Label Changes for:
Combivent Inhalation Aerosol (ipratropium bromide and albuterol sulfate) Inhalation Aerosol
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- May 2009
|The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.
- hypokalemia, mental disorder, hyperhidrosis, muscle spasms, muscular weakness, mylagia and asthenia